John E. Imhoff - 18 Dec 2025 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GTHP
Reported as of: 18 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Mar 2026, 19:52:25 UTC
Prior SEC filing: 05 Sep 2025
Next SEC filing: 07 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ John E. Imhoff

Key filing fact

John E. Imhoff filed Form 4 for GUIDED THERAPEUTICS INC (GTHP) on 12 Mar 2026.

Key facts

This page summarizes John E. Imhoff's Form 4 filing for GUIDED THERAPEUTICS INC (GTHP).
15 reported transactions and 8 derivative rows are listed below.
Accepted by SEC: 12 Mar 2026, 19:52.

Change

Previous filing in this sequence was filed on 05 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001348439 Primary reporting owner

Imhoff John E

Relationship: Director, 10%+ Owner
Address: 5853 PEACHTREE CORNERS EAST, SUITE B, PEACHTREE CORNERS
Signature: /s/ John E. Imhoff
Signature date: 12 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GTHP transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +195,460
Change %: +1%
Price: $0.0700^*
Shares after: 19,658,955
Date: 18 Dec 2025
Ownership: Direct
Footnotes: F1

GTHP transaction

Common Stock

Other

Transaction value
Shares: +25,338
Change %: +0.13%
Price
Shares after: 19,684,293
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F2

GTHP transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +312,720
Change %: +1.6%
Price: $0.0700^*
Shares after: 19,997,013
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F3

GTHP transaction

Common Stock

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: +500,000
Change %: +2.5%
Price
Shares after: 20,497,013
Date: 25 Feb 2026
Ownership: Direct
Footnotes: F4

GTHP transaction

Preferred Series E Stock

Other

Transaction value
Shares: -100
Change %: -100%
Price
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F5

GTHP transaction

Common Stock

Other

Transaction value
Shares: +400,000
Change %: +2%
Price
Shares after: 20,897,013
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F5

GTHP transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +156,086
Change %: +0.75%
Price: $0.0700^*
Shares after: 21,053,099
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTHP transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares: -195,460
Change %: -57%
Price
Shares after: 150,000
Date: 18 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 195,460
Exercise price: $0.0700
Footnotes: F1

GTHP transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares: -312,720
Change %: -71%
Price
Shares after: 130,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 312,720
Exercise price: $0.0700
Footnotes: F3

GTHP transaction Derivative

Warrants

Other

Transaction value
Shares: -500,000
Change %: -100%
Price
Shares after: 0
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.6500
Footnotes: F4

GTHP transaction Derivative

Warrants

Other

Transaction value
Shares: +500,000
Change %
Price
Shares after: 500,000
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.6500
Footnotes: F4

GTHP transaction Derivative

Warrants

Other

Transaction value
Shares: -500,000
Change %: -100%
Price
Shares after: 0
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.5000
Footnotes: F4

GTHP transaction Derivative

Warrants

Other

Transaction value
Shares: +500,000
Change %
Price
Shares after: 500,000
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.2000
Footnotes: F4

GTHP transaction Derivative

Warrants

Exercise of in-the-money or at-the-money derivative security

Transaction value
Shares: -500,000
Change %: -100%
Price
Shares after: 0
Date: 25 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 500,000
Exercise price: $0.2000
Footnotes: F4

GTHP transaction Derivative

Convertible Promissory Note

Conversion of derivative security

Transaction value
Shares: -156,086
Change %: -57%
Price: $0.0700^*
Shares after: 120,000
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 156,086
Exercise price: $0.0700
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

Footnote F2

These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.

Footnote F3

On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

Footnote F4

During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

Footnote F5

On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

Footnote F6

On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.